Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Marco Falcone, Giusy Tiseo, Alessandro Leonildi, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 5
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2023)
Open Access | Times Cited: 476
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis
Antibiotics (2022) Vol. 11, Iss. 6, pp. 723-723
Open Access | Times Cited: 147
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1072-1084
Closed Access | Times Cited: 115
Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network)
Marco Falcone, Giusy Tiseo, Sergio Carbonara, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 12, pp. 2059-2069
Open Access | Times Cited: 79
Navigating Available Treatment Options for Carbapenem-ResistantAcinetobacter baumannii-calcoaceticusComplex Infections
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Clinical Infectious Diseases (2023) Vol. 76, Iss. Supplement_2, pp. S179-S193
Open Access | Times Cited: 74
Acinetobacter baumannii in the critically ill: complex infections get complicated
Ilaria Cavallo, Alessandra Oliva, Rebecca Pages, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 55
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19
Alessandro Russo, Andrea Bruni, Sara Palma Gullì, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 1, pp. 106825-106825
Open Access | Times Cited: 46
Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis
Lorenzo Onorato, Ilaria de Luca, Caterina Monari, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106113-106113
Open Access | Times Cited: 16
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Petros I. Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, et al.
Antibiotics (2024) Vol. 13, Iss. 3, pp. 261-261
Open Access | Times Cited: 15
The Evolution of Antimicrobial Resistance in Acinetobacter baumannii and New Strategies to Fight It
Viola Camilla Scoffone, Gabriele Trespidi, Giulia Barbieri, et al.
Antibiotics (2025) Vol. 14, Iss. 1, pp. 85-85
Open Access | Times Cited: 2
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)
Giusy Tiseo, Gioconda Brigante, Daniele Roberto Giacobbe, et al.
International Journal of Antimicrobial Agents (2022) Vol. 60, Iss. 2, pp. 106611-106611
Open Access | Times Cited: 63
Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
Stefano Stracquadanio, Carmelo Bonomo, Andrea Marıno, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 38
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams
Milo Gatti, Federico Pea
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 2, pp. 149-166
Closed Access | Times Cited: 36
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
Pierluigi Viale, Christian E. Sandrock, Paula Ramírez, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
Maria Mazzitelli, Darío Gregori, Lolita Sasset, et al.
Microorganisms (2023) Vol. 11, Iss. 4, pp. 984-984
Open Access | Times Cited: 27
Acinetobacter Baumannii Phages: Past, Present and Future
Qihang Tu, Mingfang Pu, Yahao Li, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 673-673
Open Access | Times Cited: 25
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
François Barbier, Sami Hraiech, Solen Kernéis, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Novel Antimicrobial Agents for Gram-Negative Pathogens
Marios Karvouniaris, Maria Panagiota Almyroudi, Mohd H. Abdul‐Aziz, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 761-761
Open Access | Times Cited: 23
Acinetobacter Metabolism in Infection and Antimicrobial Resistance
Xiaomei Ren, Lauren D. Palmer
Infection and Immunity (2023) Vol. 91, Iss. 6
Open Access | Times Cited: 22
Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study
Emanuele Rando, Salvatore Lucio Cutuli, Flavio Sangiorgi, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 22
Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence
Francesca Serapide, Maurizio Guastalegname, Sara Palma Gullì, et al.
Antibiotics (2024) Vol. 13, Iss. 6, pp. 506-506
Open Access | Times Cited: 11
Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections
Amer El Ghali, Ashlan J. Kunz Coyne, Kristen Lucas, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 8
Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections
Burcu Isler, Abdullah Tarık Aslan, Murat Akova, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 11, pp. 1389-1400
Closed Access | Times Cited: 37
New antibiotics for Gram-negative pneumonia
Matteo Bassetti, Federica Magnè, Daniele Roberto Giacobbe, et al.
European Respiratory Review (2022) Vol. 31, Iss. 166, pp. 220119-220119
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top